Related Experiment Video
Updated: Sep 9, 2025

13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.1K
Liquid Plasma vs Thawed Plasma: Tracking Coagulation Factor Activity Changes During Storage
Medrxiv : the Preprint Server for Health Sciences
|September 2, 2025
Summary
Liquid plasma (LQP) offers a longer shelf life than thawed plasma (TP) for emergency transfusions. LQP demonstrates comparable levels of key clotting factors, making it a viable alternative for critical care scenarios.
Area of Science:
- Transfusion Medicine
- Hematology
- Biochemistry
Background:
- Liquid plasma (LQP) presents a longer shelf-life alternative to thawed plasma (TP) for emergent transfusions.
- Assessing coagulation factor stability and activity in LQP is crucial for its clinical application.
Purpose of the Study:
- To measure fibrinogen, Protein C, Protein S, FV, FVII, and FVIII activity in LQP.
- To quantify changes in these factor levels in LQP during storage.
- To compare LQP factor activity with that of TP.
Main Methods:
- Coagulation factor activities were measured in LQP (n=26) at Days 15, 26, and 27, and in TP (n=24) at Day 5.
- Bayesian statistical modeling was employed to compare factor activities and assess storage-related changes.
Main Results:
- Fibrinogen and Protein C activity in LQP at Day 26 (LQP26) were comparable to TP at Day 5 (TP5).
- FV, FVII, and FVIII activities were slightly lower in LQP26 compared to TP5.
- Protein S activity was significantly lower in LQP26 (28.0%) than in TP5 (64.9%).
- FVII activity decreased in LQP from Day 15 to Day 26, while other factors remained stable.
Conclusions:
- LQP exhibits comparable fibrinogen, Protein C, FV, FVII, and FVIII activities to TP for emergency use, with the exception of lower Protein S levels.
- LQP is a viable alternative for emergency transfusions and massive transfusion protocols due to its extended shelf life and adequate factor levels.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Coagulation
7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K

